ChristosArgyropoulos, Discover and Read the Best of Twitter Threads by @ChristosArgyrop

ChristosArgyropoulos

ChristosArgyrop

Let's analyze the dialysis case from yesterday. We need to know : a) the SAR (Secondary Attack Rate) of COVID19 for household transmission (pt had largely sheltered in, so could

#AskRenal about this scenario (answer at the end):pt on dialysis shows up with upper respiratory symptoms c/w COVID19. Entire household has same symptoms and they all got tested. Everyone is

My prescription guide of #SGLT2I - as an early adopter since late 2015 4+1 tweets which can kick start your career as a slayer of diabetic kidney disease, savior of

Alright then, time to visit this. We currently have two publications for two different SGLT2i from two different studies (CANVAS and EMPAREG-Outcome) that show that the *relative* benefits of SGLT2i

Had some more time with the clinical trials EMPEROR-Reduced and DAPA-CKD and was able to compute various composite outcomes from the major SGLT2i trials. Just posting the results here :

This 40% reduction of worsening renal function/need for dialysis seen in the SGLT2i trials (which included pts with Diabetes Type 2, except DAPA-HF/EMPEROR) has some rather implications for the business